This trial is testing whether injecting deferoxamine into the fluid around the brain and spinal cord is safe for people with cancer that has spread there. It focuses on patients with non-small cell lung cancer. The drug works by reducing the iron that cancer cells need to grow. Deferoxamine is an iron chelator approved by the FDA, commonly used to treat iron-overload diseases and has shown anticancer activity by depleting cancer cells of iron.